ABUS vs PFE
ABUS: A clinical-stage biopharmaceutical company developing novel treatments for chronic hepatitis B while generating value from its lipid nanoparticle drug delivery patent portfolio. PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
Side-by-side fundamentals
| Metric | ABUS | PFE | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $4.33 | $30.11 | |
| Market cap | $857M | $171.6B | |
| P/E as of 2026-10-20 | 5.48 | 39.62 | ABUS lower |
| Net margin FY2025, SEC XBRL | -237.9% | +12.4% | PFE higher |
| Operating margin FY2025, SEC XBRL | -271.0% | n/a | |
| ROE FY2025, SEC XBRL | -43.7% | +9.0% | PFE higher |
| ROA FY2025, SEC XBRL | -35.4% | +3.7% | PFE higher |
| Debt / equity | 0.00 | 0.74 | ABUS lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +128.2% | -1.6% | ABUS higher |
| Revenue CAGR (3y) SEC XBRL | -28.8% | -14.8% | PFE higher |
| Dividend yield as of 2026-09-02 | n/a | +6.2% | |
| Dividend streak (yrs) SEC XBRL | 0 | 11 | PFE higher |
| Beta as of 2026-09-03 | 0.95 | 0.38 | |
| 1-year return as of 2026-10-20 close | -4.8% | +22.0% | PFE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.